HempFusion Wellness (TSX: CBD.U), along with its five-channel strategy, impressive line of products and historic first day of trading after completing its $17 million IPO, were the focus of a recent article. The article outlined the power of the company, noting that it was the first U.S.-based CBD company approved for listing directly on the TSX. The article recounted the company’s strength as a leader in the health and wellness CBD industry and called out its diverse portfolio of brands, including HempFusion CBD, Probulin Probiotics, Biome Research and HF Labs; the article also noted that the company offers four dozen products ranging from tinctures to proprietary over-the-counter (“OTC”) topicals with more than 30 additional products under development. The company’s product and market diversity is one of its strengths, particularly its Probulin Probiotics brand. Launched in 2013. Probulin has since become a wholly owned subsidiary of HempFusion and ranks as one of the fastest-growing probiotic companies in the natural product space. “Our products are based on exclusive and unique raw materials that are as close to the plants’ natural fingerprint as possible,” said HempFusion co-founder and CEO in the article, who also noted that “this IPO will accelerate our ability to scale HempFusion’s operations both domestically and internationally, drive accelerated growth within all our distribution channels, and significantly expand our marketing initiatives. A large percentage of the proceeds from the IPO will be earmarked for building out our ecommerce strategy.”
To view the full article, visit https://ibn.fm/CZwV7
About HempFusion Wellness Inc.
HempFusion is a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition. HempFusion distributes its family of brands, including HempFusion, Probulin Probiotics, Biome Research and HF Labs, to approximately 4,000 retailers across all 50 states of the United States and select international locations. Built on a foundation of regulatory compliance and human safety, HempFusion’s diverse product portfolio comprises 46 SKUs (“SKUs”) including tinctures, proprietary FDA Drug Listed over-the-counter (“OTC”) topicals, doctor/practitioner lines and more. With a strong focus on research and development, HempFusion has an additional 30 products under development. HempFusion is a board member of the US Hemp Roundtable, and HempFusion’s wholly owned subsidiary, Probulin Probiotics, is one of the fastest-growing probiotics companies in the United States, according to SPINs reported data. HempFusion’s CBD products are based on a proprietary Whole Food Hemp Complex(TM) and are available in store or online. For more information about the company, visit www.HempFusion.com.
NOTE TO INVESTORS: The latest news and updates relating to HempFusion are available in the company’s newsroom at https://ibn.fm/HempFusion
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.